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ABSTRACT
The prevalence and fatality rate of asthma have increased 
worldwide. Underdiagnosis and undertreatment of asthma 
are central to the occurrence of fatal asthma. Atopy is the prin-
cipal risk factor associated with asthma. However, consider-
ation of the epidemiologic, physiologic, pharmacologic, 
pathologic and clinical parameters of asthma assessment may 
provide valuable insight into death due to asthma. Psychologic 
and socioeconomic factors may further aggravate the asthma 
status. Ethnic minorities are at increased risk of asthma. The 
perception of dyspnea may be blunted in asthma sufferers. 
Slow-onset fatal asthma may be associated with submucosal 
eosinophilia, whereas sudden-onset may be associated with 
submucosal neutrophilia. Fatal asthma occurs in patients
abusing regular β2-agonist therapy. Peak flow assessment
often provides insight into asthma deterioration prior to signs 
of respiratory distress. Markers of risk of death due to asthma 
further identify the fatality-prone asthma patient.
Key words: fatal asthma, poor perception, underdiagnosis, 
undertreatment
INTRODUCTION
Underdiagnosis, including inadequate assessment of asthma 
severity and undertreatment of the asthma sufferer, is central to 
the occurrence of near-death or fatal asthma.1,2 That asthma 
morbidity can be reduced, in fact that asthma mortality can be 
prevented, is not generally appreciated by the community as 
well as many medical practitioners. Many physicians address 
less serious disorders occurring less frequently than asthma with 
more dexterity and dedication than that with which they address 
asthma. 
 The prevalence and fatality rate of asthma has increased 
worldwide with nearly 100 million individuals now affected by
asthma.3 In the USA, asthma mortality has plateaued at nearly 
6000 deaths annually.4 Inadequate assessment of respiratory 
disability with inadequate treatment is responsible for the signifi-
cant asthma fatality rate.5 Frequently the severity of asthma is 
appreciated by neither the patient nor the clinician. Most asthma 
deaths are preventable by prompt diagnosis of asthma and early 
introduction of an appropriate therapeutic program including 
repeated evaluation with close medical supervision. Any asthma 
sufferer may be fatality-prone, particularly if the medical evalua-
tion, treatment and follow-up are inadequate. 
 Factors identified with increased risk of fatal asthma have been 
attributed to the pathologic changes in the airways and the man-
agement of asthma by the physician as well as the patient. Atopy 
is the principal risk factor associated with asthma.6 However, 
consideration of the epidemiologic, physiologic, pharmaco-
logic, pathologic and clinical parameters of asthma assessment 
may provide valuable insight into asthma deaths.7 Psychologic 
and socioeconomic factors may further aggravate the asthma 
status, but such factors usually are not primary risk contributors.
PARAMETERS OF ASTHMA ASSESSMENT 
Epidemiologic
Although there have been many epidemiologic studies of fatal or 
near-fatal asthma,8 there have been few assessments of the 
mechanisms underlying a life-threatening attack.9 Asthma preva-
lence in the USA has increased in the under-18 and over-65-
year-old age groups, whereas mortality involves mainly the 5-34 
and the over-50-year-old groups.10,11 Ethnic minorities are at par-
ticular risk. In the USA, asthma sufferers of African-American and 
Hispanic background are more prone to fatal asthma than their 
Caucasian counterparts.10 In New Zealand, the Maoris (indige-
nous Polynesians) have a significantly greaterfatality rate than the 
national average for that country.3 However, in all instances, liv-
ing in a socioeconomically deprived, crowded city center area 
may be a common predisposing factor. Such areas have an over-
abundance of sensitizing antigens such as dust mite, cockroach 
and animal allergens. In certain ethnic communities, seeking rou-
tine health assessment is not condoned. Individuals use the 
emergency room for asthma treatment only during serious 
asthma attacks. They often have inadequately controlled asthma
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which exacerbates abruptly with a possible fatal outcome if 
appropriate therapy is not readily available. Other precipitants of 
life-threatening asthma may include respiratory infection12 or even 
allergen overload including mold spores and pollen antigens.
Physiologic 
The perception of dyspnea and chemosensitivity may be reduced, 
in spite of hypoxia and hypercapnia, in patients with near-fatal 
asthma, compared with normal subjects with no asthma history.13 
Such lower hypoxic responses have been associated with a blunted 
perception of asthma severity and even impaired chemosensitivvivity 
to hypercapnia.13 These observations were further correlated with 
reductions in the mean hypoxic ventilatory response and airway 
occlusion pressure in patients with near-fatal asthma.9,13 This is 
particularly noted when compared with non-asthma or asthma 
patients who never experienced a near-fatal attack. 
  There were three patterns of respiratory decompensation 
observed in 34 patients intubated and mechanically ventilated 
for severe near-fatal asthma. Group I deteriorated rapidly after 
the onset of symptoms with endotracheal intubation in <3h. 
Group II experienced a gradual onset of respiratory failure over
days, i. e. 9.2±7.7 days, and Group III experienced acute exac-
erbation during unstable asthma, i. e. 4.2±3.5 days. It was felt
by these authors that acute bronchodilatation was central to the 
sudden asphyxic asthma.14
  The mean hypoxic ventilatory response (0.14±0.12L/min/per
cent of arterial oxygen saturation) and airway occlusion pressure
(0.05±0.95cm of water/per cent of arterial oxygen saturation)
were significantly lower in the patients with near-fatal asthma than 
in normal subjects and the patients with asthma who had not had 
near-fatal attacks. Patients with near-fatal asthma had a lower 
hypoxic response that coupled with a blunted perception of dysp-
nea when compared with normal subjects. Therefore, some 
patients may have a hereditary lower sensitivity to hypoxia which 
becomes apparent only if severe hypoxia develops during an 
exacerbation of asthma.13 So an impaired hypoxic response asso-
ciated with a reduced perception of dyspnea may result in a delay 
to seek, and therefore institute, appropriate care.12
Pathologic
Pathologic assessment of post-mortem tissues obtained from sub-
jects with fatal asthma episodes has yielded several striking obser-
vations.15,16 It is possible to differentiate two types of fatal asthma. 
Slow-onset fatal asthma was associated with submucosal 
eosinophilia, whereas sudden-onset fatal asthma was associated 
with mucosasl eosinophilia and submucosal neutrophils.15 Thus, 
submucosal eosinophil assessment correlated significantly with 
the time interval between onset and death resulting from asthma. 
 Autopsy evaluation of airway dimensions was conducted in 
asthmatic subjects with death due to asthma (fatal asthma), asth-
matic subjects with death not due to asthma (non-fatal asthma) 
and subjects without asthma (controls). Large central and small 
peripheral airway diameters were measured and then grouped 
according to the basement membrane diameter. Area was 
expressed as area/mm2 of basement membrane. In cartilaginous 
airways, fatal asthma subjects had greater total wall, inner wall, 
outer wall, smooth muscle, mucous gland and cartilage areas 
than controls (P<0.05). Non-fatal (P<0.05) asthma subjects had 
greater small cartilage airways and membranous bronchioles 
than controls.16 In the large membranous bronchioles, the area of 
smooth muscle was greater in fatal and non-fatal asthma subjects 
than in the controls (P<0.05). It was the authors' opinion that 
structural changes contributing to airway responsiveness occurred 
in large and small airways in fatal asthma. However, such 
changes were observed in the small airways in non-fatal asthma 
cases. Pulmonary functional changes consistent with large and 
small airway dysfunction may suggest airway hyper-responsive-
ness and in turn fatality-prone asthma.16
 Airway wall measurements of post-mortem tissue revealed 
increased diameter in fatal asthma compared with either non-
fatal or normal subjects.15 The fatal asthma subjects all died 
suddenly out of the hospital and had not received mechanical 
ventilation. They had long histories of asthma and had required 
prior hospitalizations for frequent episodic attacks with sus-
tained periods of airflow impairment. 
  Pathologic studies such as these provide appreciation of the 
pathochemical correlates relating to fatal asthma. The hypertro-
phied smooth muscle allows for greater shortening in response 
to bronchoconstrictor response to allergen challenge, whereas 
the increase in outer wall diameter may permit uncoupling of 
the distending force of parenchyma) recoil from the forces con-
tributing to airway recovery.
 Narrowing of the airway may be further compromised by 
mucous gland hypertrophy with excessive mucus production 
and inner-wall thickening by muscle hypertrophy.. With the 
increased recognition of early asthma airway remodelling and 
airway tissue response to therapy, assessment of the pathologic 
changes is critical to understanding fatal asthma.15,16 
 The characteristic pathologic changes occurring in fatal 
asthma usually consist of mucus-inspissated bronchi and bronchi-
oles. Usually eosinophils and desquamated epithelial cells 
occupy the airways, which may be distended with emphysematous 
changes and thickened basement membrane, now recognized to 
be the results of airway remodelling.17-19 Occasional post-mortem 
examination is devoid of inflammatory changes but complicated 
by pneumothorax, cor pulmonary, aspiration, pneumonia and/or 
p lmonary edema.20 There usually is an inflammatory compo-
nent, further substantiating inadequate treatment.8
Pharmacologic
Fatal asthma has occurred when patients use regular β2-agonist
therapy.21 In some instances these patients were not administer-
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ing concomitant anti-inflammatory therapy. The role of regular
versus intermittent (on-demand) β2-agonist therapy remains
controversial.21 β2-agonist-induced protection against induced
bronchospasm is attenuated with long-term regular abbreviated 
therapy.22 Regular administration of inhaled terbutaline for 7 
days lost the protective effect of a single dose of inhaled terbu-
taline against the bronchoconstriction induced by adenosine 
monophosphate and methacholine. In these studies, the inhibi-
tion of the bronchoconstricting agent was reduced by 2.1 and 
1.5 doubling doses respectively. Salmeterol affords significant 
protection against methacholine-induced bronchoconstriction 
which is diminished after 4-8 weeks of treatment.23
Repeated use of inhaled β2-agonists may be associated with
deterioration in control of asthma with an increase in airway 
hyper-responsiveness.24-26 Regularly scheduled or frequent use
of short-acting β2-agonists for prolonged management of
asthma fails to adequately control asthma symptoms, peak flow 
variability and/or airway hyper-responsiveness.21 Regular
administration of β2-agonists to mild asthma sufferers was asso-
ciated with an increase in peak expiratory flow variability. After 
cessation of treatment there was a 10% fall in forced expiratory 
volume in one second (FEV1) and an increase in bronchial reac-
tivity to histamine. Such changes occur with terbutaline,24-26 
fenoterol,21 and albuterol.27 
 The mechanism contributing to the increase in bronchial reac-
tivity and deterioration in asthma control after β2-agonist therapy
is unclear. Desensitization of β2-receptor has been postu-
lated,24,28 with smooth muscle relaxation and enhanced mediator 
release.
  Fenoterol has been associated with an increase in fatal 
asthma when administered regularly,3,29 Assessment of fatal and 
near-fatal asthma in a nested case control study in Saskat-
chewan, Canada, confirmed the relationship of fatal asthma to
β2-agonist abuse.30 The risk of asthma increased when 1.4 can-
isters or more of β2-agonist were consumed. It is yet to be deter-
mined whether the increased use of β2-agonist in fatal or
near-fatal asthma contributes to mortality or is merely a marker 
of severe disease.30
 At least one study of near-fatal asthma suggests such exacer-
bations are related to severe asphyxia rather than cardiac 
arrhythmia,31 making undertreatment a significant contribution 
to asthma mortality.32 Psychotropic drug administrations were 
also associated with an increased risk of death, whereas corti-
costeroids were only slightly associated with subsequent death, 
more strongly associated with read mission.32
Clinical
Can the fatality-prone asthma sufferer be identified? If so, what 
are the markers for the risk of asthma death? In thirty-nine 
deaths due to asthma in patients not prescribed fenoterol,8,29,32 
hospital admission in the previous year for asthma treatment 
was the strongest indicator of subsequent risk of death and a
strong marker for increased readmission for asthma. The risk of 
death was increased with the number of previous admissions. 
 Ascertai ing asthma s verity by historical evidence or peak 
flow valuation provides additional insights into the increased 
risk of death due to asthma. A peak expiratory flow rate (PEFR) 
<100 L/min caused a 2-fold risk of subsequent death or read-
mi sion. A PCO2>45mmHg was associated with an increased 
risk of death.32 It is critical to classify asthma by severity; mild, 
moderate and severe." This is now the basis of the zonal step-
w se therapy initially proposed in the National Heart, Lung and 
Blood Institute (NHLBI) International Consensus for the 
Diagnosis and Treatment of Asthma, and further refined by the 
World Health Organization/NHLBI Global Strategy for Asthma 
(GSA).11
  Patients with severe asthma requiring three or more admis-
sions/year and who had a very severe attack within the same year 
are highly susceptible to fatal attacks of asthma.11 A history of pre-
vio s life-threatening attacks is associated with a 3-fold risk of 
death wh n compared with individuals whose asthma is treated 
on an outpatient basis. A previous life-threatening attack is asso-
ciated with a 14-fold increased risk of death, whereas a previous 
hospit l admission is associated with a 7-fold increased risk.11
 Therefore there are three markers which indicate the risk of 
death due to asthma. First, a hospital admission for asthma in 
the previous 12 months is the most consistent predictor of a fatal 
asthma att ck.11 Second, multiple hospital admissions for 
asthm  in th  previou  year are associated with an even greater 
increased risk. Third, the chronic use of three or more cate-
gories of asthma drugs has an increased risk of asthma fatal-
ity.11 Oral corticosteroid drug administration had only a weak 
ssociation with subsequent risk of death. As markers of a 
severe attack, PCO2>45mmHg and PEFR 100L/min are consis-
tent with a life-threatening attack.32
 Other clinical factors contributing to fatal asthma attacks 
include inad quate assessment of asthma severity by the clini-
cian as well as the patient, i. e. underdiagnosis with resulting 
und treatment.15 Therefore, assessment must include evalua-
tion by objective parameters with a peak flow meter correlated 
with the clinical manifestations. This is particularly true of fatal-
ity-prone asthmatics who may have a poor or inadequate 
nderstandina of their asthma severity.
  Evaluation of such a fatality-prone asthma sufferer should 
include response to therapy, i. e. beneficial, no change, worse, 
in reference to the clinical status as well as appraisal of lung 
function after therapeutic intervention. 
  Undertreatment, or more specifically inappropriate treatment, 
occurs when pulmonary functional assessment is infrequently 
obtained and with over-reliance on frequently administered 
bronchodilation therapy to treat the underlying pathophysiologic 
changes, i. e. inflammation, of fatal asthma.11 Other manage-
ment factors contributing to fatal asthma risk factors include dis-
continuity of medical care and delays in seeking medical 
ttention. Delays in seeking care are often related to the absence
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Table 1. Risk factors
of a written prepared plan for treating asthma exacerbations as 
well as inadequate access to emergency medical care.8,11 
 Chronic disability due to asthma, as in other long-term disor-
ders, may lead to aberrant behaviour and depression. Children 
may be particularly afflicted by a false sense of hopelessness. 
Asthma cannot be cured, but it can be controlled. Although 
information linking depression and increased asthma fatalities 
is derived principally from clinical reports,5 the association is 
striking in a review of cases where children died suddenly and 
unexpectedly of asthma. There is clinical evidence that these 
children had expressed despair, hopelessness, even a desire to 
die, and other evidence of depression. 
  Occasionally, patients who have experienced life-threatening 
asthma exacerbations have been observed to deny that they are 
at risk of death. Often after a near-fatal exacerbation of 
asthma, such affected children tend to develop decompensating
psychiatric disorders, symptoms of extreme anxiety or even high 
levels of denial. Other patients minimize their symptoms and 
avoid appropriate health care. Therefore, as a result of the 
physiologic and psychologic interactions leading to anxiety, 
depression and possible fatal asthma episodes, such affected 
patients require specific professional intervention.5
CONCLUSION
Fatal asthma results from underdiagnosis and undertreatment. 
Although those suffering from severe persistent asthma, or even 
those with mild intermittent asthma, may sufferfrom a life-threaten-
ing or even fatal exacerbation of asthma. To prevent such fatal 
occurrences, it is critical to identify and correct those factors that 
accentuate risk of death from asthma. There are several parame-
ters to identify patients at high risk of fatal asthma. The greatest risk 
to the individual with asthma is complacency or underestimation of 
the severity of asthma by the patient, the patient's family, or even 
the patient's physician. The risk can be mitigated by appropriate 
identification of the patient at high risk for fatal asthma through 
careful assessment of the risk factors (Table 1).
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